Harmony Biosciences Holdings, Inc. announced preliminary, unaudited net product revenues for the fourth quarter and full year ended December 31, 2024. For the quarter, the company reported net product revenue was approximately $201 million, compared to $168.4 million for the same period in 2023.

For the full year, the company reported net product revenue was approximately $714 million, compared to $582 million for the same period in 2023, representing ~23% growth in its fifth year on the market .